{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:26:45Z","timestamp":1794914805597,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Strategic Targeting of Registries and International Database of Excellence (STRIDE) is an ongoing, international, multicenter registry of real-world ataluren use in individuals with nonsense mutation Duchenne muscular dystrophy (nmDMD) in clinical practice. This updated interim report (data cut-off: January 31, 2022), describes STRIDE patient characteristics and ataluren safety data, as well as the effectiveness of ataluren plus standard of care (SoC) in STRIDE versus SoC alone in the Cooperative International Neuromuscular Research Group (CINRG) Duchenne Natural History Study (DNHS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients are followed up from enrollment for at least 5\u00a0years or until study withdrawal. Propensity score matching was performed to identify STRIDE and CINRG DNHS patients who were comparable in established predictors of disease progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      As of January 31, 2022, 307 patients were enrolled from 14 countries. Mean (standard deviation [SD]) ages at first symptoms and at genetic diagnosis were 2.9 (1.7) years and 4.5 (3.7) years, respectively. Mean (SD) duration of ataluren exposure was 1671 (56.8) days. Ataluren had a favorable safety profile; most treatment-emergent adverse events were mild or moderate and unrelated to ataluren. Kaplan\u2013Meier analyses demonstrated that ataluren plus SoC significantly delayed age at loss of ambulation by 4\u00a0years (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) and age at decline to %-predicted forced vital capacity of\u2009&lt;\u200960% and\u2009&lt;\u200950% by 1.8\u00a0years (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0021) and 2.3\u00a0years (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0207), respectively, compared with SoC alone.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-term, real-world treatment with ataluren plus SoC delays several disease progression milestones in individuals with nmDMD. NCT02369731; registration date: February 24, 2015.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-023-11687-1","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T07:03:09Z","timestamp":1682665389000},"page":"3896-3913","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Safety and effectiveness of ataluren in patients with nonsense mutation DMD in the STRIDE Registry compared with the CINRG Duchenne Natural History Study (2015\u20132022): 2022 interim analysis"],"prefix":"10.1007","volume":"270","clinical-trial-number":[{"clinical-trial-number":"nct02369731","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Eugenio","family":"Mercuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s Nascimento","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9102-5232","authenticated-orcid":false,"given":"Francesco","family":"Muntoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Buccella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Desguerre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1r","family":"Tulinius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Bernadete Dutra","family":"de Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren P.","family":"Morgenroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2330-5427","authenticated-orcid":false,"given":"Heather","family":"Gordish-Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6139-7473","authenticated-orcid":false,"given":"Christian","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiota","family":"Trifillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik K.","family":"Henricson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the STRIDE and CINRG DNHS investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"11687_CR1","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol 17:251\u2013267","journal-title":"Lancet Neurol"},{"key":"11687_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochmueller H (2020) Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol 35:643\u2013653","journal-title":"Eur J Epidemiol"},{"issue":"8","key":"11687_CR3","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.nmd.2013.05.008","volume":"23","author":"JA Ellis","year":"2013","unstructured":"Ellis JA, Vroom E, Muntoni F (2013) 195th ENMC International Workshop: Newborn screening for Duchenne muscular dystrophy December 14\u201316th, 2012, Naarden, The Netherlands. Neuromuscul Disord 23(8):682\u2013689","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"11687_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N et al (2017) The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis 12(1):79","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"11687_CR5","first-page":"122","volume":"35","author":"L Bello","year":"2016","unstructured":"Bello L, Pegoraro E (2016) Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy. Acta Myol 35(3):122\u2013127","journal-title":"Acta Myol"},{"key":"11687_CR6","unstructured":"European Medicines Agency. Translarna\u2122 summary of product characteristics. www.ema.europa.eu\/documents\/product-information\/translarna-epar-product-information_en.pdf. Accessed 16 Apr 2022"},{"key":"11687_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1146\/annurev-med-120611-144851","volume":"64","author":"SW Peltz","year":"2013","unstructured":"Peltz SW, Morsy M, Welch EM, Jacobson A (2013) Ataluren as an agent for therapeutic nonsense suppression. Annu Rev Med 64:407\u2013425","journal-title":"Annu Rev Med"},{"issue":"44","key":"11687_CR8","doi-asserted-by":"publisher","first-page":"12508","DOI":"10.1073\/pnas.1605336113","volume":"113","author":"B Roy","year":"2016","unstructured":"Roy B, Friesen WJ, Tomizawa Y et al (2016) Ataluren stimulates ribosomal selection of near-cognate tRNAs to promote nonsense suppression. Proc Natl Acad Sci USA 113(44):12508\u201312513","journal-title":"Proc Natl Acad Sci USA"},{"key":"11687_CR9","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0086","author":"F Muntoni","year":"2019","unstructured":"Muntoni F, Desguerre I, Guglieri M et al (2019) Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patient demographics and characteristics from the STRIDE Registry. J Comp Eff Res. https:\/\/doi.org\/10.2217\/cer-2019-0086","journal-title":"J Comp Eff Res"},{"issue":"5","key":"11687_CR10","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2217\/cer-2019-0171","volume":"9","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Muntoni F, Osorio AN et al (2020) Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study. J Comp Eff Res 9(5):341\u2013360","journal-title":"J Comp Eff Res"},{"key":"11687_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2018) Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet 391:451\u2013461","journal-title":"Lancet"},{"issue":"1","key":"11687_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/mus.23807","volume":"48","author":"CM McDonald","year":"2013","unstructured":"McDonald CM, Henricson EK, Abresch RT et al (2013) The cooperative international neuromuscular research group Duchenne natural history study: a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve 48(1):32\u201354","journal-title":"Muscle Nerve"},{"key":"11687_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/2050312119840518","author":"JG Andrews","year":"2019","unstructured":"Andrews JG, Pandya S, Trout C, Jaff T, Matthews D, Cunniff C (2019) Palliative care services in families of males with muscular dystrophy: data from MD STARnet. SAGE Open Med. https:\/\/doi.org\/10.1177\/2050312119840518","journal-title":"SAGE Open Med"},{"issue":"8","key":"11687_CR14","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1007\/s11999-015-4239-4","volume":"473","author":"MCS Inacio","year":"2015","unstructured":"Inacio MCS, Chen Y, Paxton EW, Namba RS, Kurtz SM, Cafri G (2015) Statistics in brief: an introduction to the use of propensity scores. Clin Orthop Relat Res 473(8):2722\u20132276","journal-title":"Clin Orthop Relat Res"},{"key":"11687_CR15","doi-asserted-by":"publisher","DOI":"10.2217\/vjbm-2022-0014","author":"E Mercuri","year":"2022","unstructured":"Mercuri E (2022) Propensity score matching methodology. Video J Biomed. https:\/\/doi.org\/10.2217\/vjbm-2022-0014","journal-title":"Video J Biomed"},{"key":"11687_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM et al (2018) Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management. Lancet Neurol 17:347\u2013361","journal-title":"Lancet Neurol"},{"issue":"2","key":"11687_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ejpn.2011.07.001","volume":"16","author":"V Humbertclaude","year":"2012","unstructured":"Humbertclaude V, Hamroun D, Bezzou K et al (2012) Motor and respiratory heterogeneity in Duchenne patients: implication for clinical trials. Eur J Paediatr Neurol 16(2):149\u2013160","journal-title":"Eur J Paediatr Neurol"},{"issue":"12","key":"11687_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1164\/ajrccm.164.12.2103052","volume":"164","author":"MF Phillips","year":"2001","unstructured":"Phillips MF, Quinlivan RC, Edwards RH, Calverley PM (2001) Changes in spirometry over time as a prognostic marker in patients with Duchenne muscular dystrophy. Am J Respir Crit Care Med 164(12):2191\u20132194","journal-title":"Am J Respir Crit Care Med"},{"key":"11687_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3389\/fneur.2017.00196","volume":"8","author":"L Wang","year":"2017","unstructured":"Wang L, Chen M, He R et al (2017) Serum creatinine distinguishes duchenne muscular dystrophy from becker muscular dystrophy in patients aged \u22643 years: a retrospective study. Front Neurol 8:196","journal-title":"Front Neurol"},{"issue":"4","key":"11687_CR20","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3233\/JND-160185","volume":"3","author":"J Vry","year":"2016","unstructured":"Vry J, Gramsch K, Rodger S et al (2016) European cross-sectional survey of current care practices for Duchenne muscular dystrophy reveals regional and age-dependent differences. J Neuromuscul Dis 3(4):517\u2013527","journal-title":"J Neuromuscul Dis"},{"issue":"5","key":"11687_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nmd.2017.02.006","volume":"27","author":"A D'Amico","year":"2017","unstructured":"D\u2019Amico A, Catteruccia M, Baranello G et al (2017) Diagnosis of Duchenne muscular dystrophy in Italy in the last decade: critical issues and areas for improvements. Neuromuscul Disord 27(5):447\u2013451","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"11687_CR22","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B et al (2014) Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve 50(4):477\u2013487","journal-title":"Muscle Nerve"},{"issue":"10101","key":"11687_CR23","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE et al (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390(10101):1489\u20131498","journal-title":"Lancet"},{"issue":"3","key":"11687_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2217\/cer-2021-0196","volume":"11","author":"CM McDonald","year":"2022","unstructured":"McDonald CM, Muntoni F, Penematsa V et al (2022) Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients. J Comp Eff Res 11(3):139\u2013155","journal-title":"J Comp Eff Res"},{"issue":"2","key":"11687_CR25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ et al (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9(2):177\u2013189","journal-title":"Lancet Neurol"},{"key":"11687_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.17925\/USN.2017.13.01.35","volume":"13","author":"OH Mayer","year":"2017","unstructured":"Mayer OH, Henricson E, McDonald C, Buyse G (2017) Advances in pulmonary care in duchenne muscular dystrophy. US Neurol 13:35\u201341","journal-title":"US Neurol"},{"issue":"1","key":"11687_CR27","doi-asserted-by":"publisher","first-page":"e52512","DOI":"10.1371\/journal.pone.0052512","volume":"8","author":"ES Mazzone","year":"2013","unstructured":"Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, Torrente Y et al (2013) 24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. PLoS ONE 8(1):e52512. https:\/\/doi.org\/10.1371\/journal.pone.0052512","journal-title":"PLoS ONE"},{"issue":"4","key":"11687_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1212\/WNL.0000000000002891","volume":"87","author":"L Bello","year":"2016","unstructured":"Bello L, Morgenroth LP, Gordish-Dressman H et al (2016) DMD genotypes and loss of ambulation in the CINRG Duchenne natural history study. Neurology 87(4):401\u2013409","journal-title":"Neurology"},{"issue":"2","key":"11687_CR29","first-page":"149","volume":"87","author":"V Ricotti","year":"2016","unstructured":"Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, Manzur AY et al (2016) The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials. J Neurol Neurosurg Psychiatry 87(2):149\u2013155","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"11687_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mus.27427","volume":"65","author":"F Trucco","year":"2022","unstructured":"Trucco F, Ridout D, Domingos J, Maresh K, Chesshyre M, Munot P, Sarkozy A et al (2022) Genotype-related respiratory progression in Duchenne muscular dystrophy\u2014a multicenter international study. Muscle Nerve 65(1):67\u201374","journal-title":"Muscle Nerve"},{"issue":"2","key":"11687_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/jcsm.12914","volume":"13","author":"M Chesshyre","year":"2022","unstructured":"Chesshyre M, Ridout D, Hashimoto Y, Ookubo Y, Torelli S, Maresh K, Ricotti V et al (2022) Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy. J Cachexia Sarcopenia Muscle 13(2):1360\u20131372","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"11687_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201626","author":"F Muntoni","year":"2023","unstructured":"Muntoni F, Signorovitch J, Sajeev G, Lane H, Jenkins M, Dieye I, Ward SJ et al (2023) DMD genotypes and motor function in duchenne muscular dystrophy: a multi-institution meta-analysis with implications for clinical trials. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000201626","journal-title":"Neurology"},{"issue":"15","key":"11687_CR33","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1001\/jama.2022.4315","volume":"327","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB et al (2022) Effect of different corticosteroid dosing regimens on clinical outcomes in boys with duchenne muscular dystrophy: a randomized clinical trial. JAMA 327(15):1456\u20131468","journal-title":"JAMA"}],"updated-by":[{"DOI":"10.1007\/s00415-023-11864-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11687-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11687-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11687-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T13:04:15Z","timestamp":1689599055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11687-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["11687"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11687-1","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-023-11864-2","URL":"https:\/\/doi.org\/10.1007\/s00415-023-11864-2","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EM has acted as an advisory board member for AveXis, Biogen, BioMarin, Bristol-Myers Squibb, Ionis Pharmaceuticals, Italfarmaco, Prosensa, PTC Therapeutics, Roche, Santhera Pharmaceuticals, Sarepta Therapeutics and Summit Therapeutics. ANO has received speaker and consultancy fees from PTC Therapeutics and is an investigator on clinical trials sponsored by Biogen, Italfarmaco, Roche, Sarepta Therapeutics and TAMDMD. FM has received consultancy fees from Akashi Therapeutics, Biogen, BioMarin, Catabasis, Italfarmaco, Pfizer, PTC Therapeutics, Roche, Sarepta Therapeutics and Tivorsan Pharmaceuticals, and is supported by University College London, London, UK, and the National Institute of Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children, National Health Service Foundation Trust. FB has received consultancy fees from PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics. ID has received consultancy fees from AveXis, Biogen, BioMarin and PTC Therapeutics. JK has acted as a consultant for Biogen, Novartis, Pfizer, PTC Therapeutics, Roche and Scholar Rock and has received research support for taking part in clinical research from Biogen, Novartis, PTC Therapeutics and Roche. MT has received lecture fees from Biogen and PTC Therapeutics; has acted as a consultant on DMD clinical trials for BioMarin, PTC Therapeutics, ReveraGen BioPharma and Sarepta Therapeutics; and has acted as an advisory board member for AveXis, Biogen and PTC Therapeutics. LM is a part owner of TRiNDS. HGD has served as a consultant for AGADA Biosciences, ReveraGen BioPharma and Solid GT, and is a cofounder and part owner of TRiNDS. SJ, AK and PT are full-time employees of PTC Therapeutics, Inc. CW is a full-time employee of PTC Therapeutics GmbH. EH has acted as a consultant on clinical trials of DMD for Capricor Therapeutics, Epirium Bio (formerly Cardero Therapeutics), Mallinckrodt Pharmaceuticals, Pfizer, PTC Therapeutics, Sanofi Genzyme, Santhera Pharmaceuticals and Sarepta Therapeutics. CM has served as a consultant for clinical trials with Astellas Pharma, Avidity Biosciences, BioMarin Pharmaceutical, Capricor Therapeutics, Catabasis Pharmaceuticals, Edgewise Therapeutics, Entrada Therapeutics, Epirium Bio (formerly Cardero Therapeutics), FibroGen, Hoffman La Roche, Italfarmaco, Pfizer, PTC Therapeutics, Santhera Pharmaceuticals Sarepta Therapeutics and Solid Biosciences. He has received research support for clinical trials from Capricor Therapeutics, Catabasis Pharmaceuticals, Edgewise Therapeutics, Italfarmaco, Pfizer, PTC Therapeutics, Santhera Pharmaceuticals and Sarepta Therapeutics. He serves on external advisory boards related to DMD for BioMarin Pharmaceutical, Capricor Therapeutics, Edgewise Therapeutics, Eli Lilly, PTC Therapeutics, Sarepta Therapeutics and Santhera Pharmaceuticals. MBDR reports no disclosures of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Before any patient is enrolled and study-related data are collected, ethics committee approval of the protocol, informed consent form and all patient enrollment materials are obtained in each country and for each site, as applicable. The study is conducted in accordance with the ethical principles outlined in the Declaration of Helsinki, applicable privacy laws and local regulations for each participating site, as well as with the Guidelines for Good Pharmacoepidemiology Practices.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical conduct of research"}}]}}